Expertise in
7
conditions

Giorgio V. Scagliotti

Turin, IT 
Expertise in
7
conditions
Turin, IT 

Overview

Giorgio Scagliotti practices practicing medicine in Turin, Italy.

Scagliotti is highly rated in 7 conditions, according to our data. Their clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Small Cell Lung Cancer (SCLC), and Orchiectomy.

They are actively involved in clinical research, co-authoring 290 peer reviewed articles and participating in 3 clinical trials.

Locations

Turin, Italy
Other Locations
Orbassano, 10043, Italy
Perugia, Italy
San Luigi, Italy
Gonzaga, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 2
ODM-201 Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) Previously Treated With Novel Hormonal Agents and Non-progressive Disease After Subsequent Treatment With a Taxane: A Multicenter Randomized Double-blind Placebo-controlled Phase II Trial.
ODM-201 Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) Previously Treated With Novel Hormonal Agents and Non-progressive Disease After Subsequent Treatment With a Taxane: A Multicenter Randomized Double-blind Placebo-controlled Phase II Trial.
Enrollment Status: Terminated
Publish Date: March 13, 2024
Intervention Type: Other, Drug
Study Drug: ODM-201
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: March 20, 2023
Intervention Type: Drug
Study Drugs: CB-839, Cabozantinib
Study Phase: Phase 2
View 2 Less Clinical Trials

290 Total Publications

Targeting a novel metabolic vulnerability of non-small cell lung cancer to fatty acid oxidation surmounts chemoresistance.
Targeting a novel metabolic vulnerability of non-small cell lung cancer to fatty acid oxidation surmounts chemoresistance.
Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
Published: December 13, 2025

Frequently Asked Questions about Giorgio V. Scagliotti

Is Giorgio V. Scagliotti a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Giorgio V. Scagliotti is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Giorgio V. Scagliotti participate in research or clinical trials?

Yes. Giorgio V. Scagliotti has published 290 articles and abstracts on conditions like Lung Cancer. You can view a list of Giorgio V. Scagliotti's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Scagliotti's expertise for a condition
ConditionClose
    View All 29 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile